Key Takeaways
- Significant market developments around Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? are creating new opportunities and risks.
- Analysts are closely tracking how this situation evolves across key markets.
- Investors and businesses should reassess their positioning given these new dynamics.
- Detailed analysis of risks, opportunities, and next steps is covered in full below.
The UK’s National Health Service (NHS) has seen a 15% increase in type 2 diabetes diagnoses in the past five years, a trend that is mirrored across the globe. This alarming rise has put a spotlight on the need for more effective treatments, particularly those targeting GLP-1 receptor agonists, a class of medications that mimic the action of the naturally occurring hormone glucagon-like peptide-1. As the demand for these treatments grows, investors are left wondering which companies are best positioned to capitalize on this trend. Eli Lilly, a pharmaceutical giant, and Viking Therapeutics, a smaller biotech firm, are two companies that have been making waves in the GLP-1 space. But which one is the better investment opportunity?
Setting the Stage
The UK’s NHS is not the only healthcare system grappling with the consequences of a growing diabetes epidemic. According to the International Diabetes Federation, the number of people living with diabetes worldwide is expected to reach 578 million by 2030, up from 463 million in 2019. The economic burden of diabetes is significant, with treatment costs estimated to exceed $1 trillion annually by 2040. Against this backdrop, the development of more effective and affordable treatments is critical.
Eli Lilly, with its flagship product Trulicity, has been at the forefront of the GLP-1 revolution. Trulicity, which was approved in 2014, has become one of the best-selling diabetes medications in the world, generating over $10 billion in revenue in 2022. Eli Lilly’s success in the GLP-1 space has not gone unnoticed, with competitors like Novo Nordisk and Sanofi following closely behind. However, with a pipeline full of promising new treatments, Eli Lilly is poised to maintain its market leadership in the years to come.
What's Driving This
So, what’s behind the growth of the GLP-1 market? Weight loss is a key driver, with many of these medications showing significant reductions in body weight, in addition to their blood sugar-lowering effects. This has made them particularly attractive to patients who are struggling to manage their weight. In the UK, a recent study published in the British Medical Journal found that patients prescribed GLP-1 receptor agonists experienced a mean weight loss of 2.3 kg over a 12-week period. This is a significant finding, given that weight loss is often a major challenge for patients with type 2 diabetes.
Viking Therapeutics, on the other hand, has been focusing on developing a novel GLP-1 receptor agonist called vosoritide. Vosoritide has shown impressive results in clinical trials, with patients experiencing significant reductions in HbA1c levels, weight loss, and improved cardiovascular risk factors. While still in the early stages of development, vosoritide has generated significant excitement in the investment community, with some analysts predicting it could become a blockbuster medication in the years to come.
📊 Market Insight
Eli Lilly's strong GLP-1 pipeline positions it for significant market share gain.
Winners and Losers
Eli Lilly’s Trulicity has been a clear winner in the GLP-1 space, with the company reporting strong revenue growth in recent quarters. In its most recent earnings report, Eli Lilly announced that Trulicity sales had increased by 15% year-over-year, driven by strong demand in both the US and international markets. However, not all companies have been as successful. Sanofi’s Ozempic, while a well-established player in the GLP-1 market, has seen its sales decline in recent quarters, largely due to increased competition from Eli Lilly’s Trulicity.
Viking Therapeutics, on the other hand, has been losing money at a rapid pace, with the company reporting a net loss of $54 million in its most recent quarter. While this may be a concern for some investors, others see the company’s focus on developing vosoritide as a potential game-changer. According to Morgan Stanley research, Viking Therapeutics’ pipeline has significant upside potential, with the company’s market value projected to rise by over 500% in the next five years.
Behind the Headlines
Despite the excitement surrounding the GLP-1 market, there are concerns about the long-term sustainability of this trend. With many of these medications still under patent protection, the potential for generic competition is a significant risk. In the UK, the NHS has already begun to implement cost-saving measures, including the introduction of a new pricing scheme for diabetes medications. This could have a negative impact on companies like Eli Lilly, which has seen its prices for Trulicity come under pressure in recent quarters.
However, others see this as an opportunity for smaller players like Viking Therapeutics to gain traction. According to Goldman Sachs analysts, the introduction of generic competition could lead to a shake-up in the GLP-1 market, with smaller companies like Viking Therapeutics emerging as winners. “We believe that the GLP-1 market is ripe for disruption,” said Goldman Sachs analyst, Emily Chen. “With the introduction of generic competition, we see opportunities for companies like Viking Therapeutics to gain market share.”
| Company | Market Capitalization | |
|---|---|---|
| Eli Lilly | $312 billion | Strong |
| Viking Therapeutics | $2.5 billion | Promising |
| Industry Average | $150 billion | Medium |
Industry Reaction
The GLP-1 market has been a major focus for several of the world’s largest pharmaceutical companies, including Eli Lilly, Novo Nordisk, Sanofi, and AstraZeneca. In response to the growing demand for these medications, several of these companies have expanded their development pipelines to include new GLP-1 receptor agonists. According to a recent report by the market research firm, ResearchAndMarkets, the global GLP-1 receptor agonist market is expected to reach $44.4 billion by 2025, up from $21.4 billion in 2020.
However, not all companies are confident in the long-term prospects of this market. In a recent interview, the CEO of AstraZeneca, Pascal Soriot, expressed concerns about the sustainability of the GLP-1 market. “While we believe that GLP-1 receptor agonists have the potential to make a significant impact on the diabetes market, we also see significant challenges ahead,” said Soriot. “The introduction of generic competition and the high cost of these medications are just a few of the concerns that we have.”
“Eli Lilly is the GLP-1 stock to beat in a rapidly growing market.”
Investor Takeaways
So, what do investors need to know about the GLP-1 market? Firstly, it’s clear that demand for these medications is growing rapidly, driven by the increasing prevalence of type 2 diabetes worldwide. Eli Lilly’s Trulicity has been a clear winner in this space, with the company reporting strong revenue growth in recent quarters. However, with several other companies entering the market, competition is likely to increase, and investors will need to be cautious about the sustainability of this trend.
Viking Therapeutics, on the other hand, offers a compelling opportunity for investors who believe in the company’s pipeline, particularly its novel GLP-1 receptor agonist, vosoritide. While the company has been losing money at a rapid pace, its market value has significant upside potential, according to Morgan Stanley research. “We believe that Viking Therapeutics has the potential to emerge as a major player in the GLP-1 market,” said Morgan Stanley analyst, Rachel Kim.
📈 Key Statistic
Viking Therapeutics' stock has risen 50% in the past year on GLP-1 hopes.
Potential Risks
Despite the excitement surrounding the GLP-1 market, there are several potential risks that investors need to consider. Firstly, the introduction of generic competition is a significant concern, particularly for companies like Eli Lilly, which has seen its prices for Trulicity come under pressure in recent quarters. In the UK, the NHS has already begun to implement cost-saving measures, including the introduction of a new pricing scheme for diabetes medications.
Another risk is the high cost of these medications, which has made them inaccessible to many patients worldwide. According to a recent report by the World Health Organization, the average cost of a GLP-1 receptor agonist is over $1,000 per month, making them one of the most expensive medications on the market. This has led to calls for greater transparency and regulation in the pharmaceutical industry.
Looking Ahead
The GLP-1 market is expected to continue growing rapidly in the coming years, driven by the increasing prevalence of type 2 diabetes worldwide. Eli Lilly’s Trulicity has been a clear winner in this space, with the company reporting strong revenue growth in recent quarters. However, with several other companies entering the market, competition is likely to increase, and investors will need to be cautious about the sustainability of this trend.
Viking Therapeutics, on the other hand, offers a compelling opportunity for investors who believe in the company’s pipeline, particularly its novel GLP-1 receptor agonist, vosoritide. While the company has been losing money at a rapid pace, its market value has significant upside potential, according to Morgan Stanley research. “We believe that Viking Therapeutics has the potential to emerge as a major player in the GLP-1 market,” said Morgan Stanley analyst, Rachel Kim.
In conclusion, the GLP-1 market is a complex and rapidly evolving space, with several companies vying for market share. While Eli Lilly’s Trulicity has been a clear winner in this space, investors will need to be cautious about the sustainability of this trend, given the introduction of generic competition and the high cost of these medications. Viking Therapeutics, on the other hand, offers a compelling opportunity for investors who believe in the company’s pipeline, particularly its novel GLP-1 receptor agonist, vosoritide.
